This article is more than 5 years old. Information may no longer be current.
Intracorneal inlays showing promise for emmetropic presbyopic patients
Click Here to Manage Email Alerts
BOSTON — Small-diameter intracorneal inlays are a promising technology for treating presbyopia in emmetropic patients, according to a surgeon speaking here.
Roger F. Steinert, MD, discussed the potential for the implants at the American Society of Cataract and Refractive Surgery Summer Refractive Congress. He gave the presentation on behalf of Richard L. Lindstrom, MD, who was unable to present.
Dr. Steinert outlined the results of preliminary trials of four intracorneal lenses: Bausch & Lomb's Chiron lens, Biovision's Invue Intracorneal Microlens system, the Intralens Multifocal Cornea, and the AcuFocus small diameter intracorneal inlay.
Bausch & Lomb's Chiron implant was well-tolerated biologically in a preliminary study, with few pigment deposits seen on the device. Of eight patients implanted monocularly with the lens in a modified monovision approach, 75% never wear glasses, Dr. Steinert said.
Biovision's Invue Intracorneal Microlens system had a high level of patient satisfaction in a preliminary clinical study, he said, with patients immediately regaining near vision after surgery.
The Intralens Multifocal Cornea, which is further along in development, is demonstrating good results in U.S. clinical trials for hyperopia, Dr. Steinert said. The implant is showing "promising" results for treating presbyopia, he said.
In clinical studies of the AcuFocus Corneal Inlay, patients are also achieving significant improvements in near visual acuity, with no loss of distance vision, he said.